A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
Clinical trial NCT04691388 · COMPLETED
Trial details
- NCT number
- NCT04691388
- Sponsor
- Zhejiang Cancer Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2024-09-04
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.